Interní Med. 2013; 15(2): 49-50
Dipeptidyl peptidase-4 inhibitors
- Diabetologická ambulance, Poliklinika Barrandov, Praha
The cells of the small intestine produce two hormones belonging to the incretin system – glucagon-like peptide-1 (GLP-1) and gastric
inhibitory polypeptide (GIP). Their secretion increases mainly postprandially. Reduced postprandial increase in GLP-1 and reduced
sensitivity of pancreatic beta cells to the effects of GLP-1 and GIP have been demonstrated in type 2 diabetics in comparison with nondiabetic
individuals. In type 2 diabetes mellitus, the enzyme dipeptidyl peptidase-4 (DPP-4) known to rapidly degrade incretins also
contributes to the insufficient effect of incretins even when the glucose level is high.
Keywords: glucagon-like peptide-1, gastric inhibitory polypeptide, dipeptidyl peptidase-4, dipeptidyl peptidase-4 inhibitors
Published: March 8, 2013 Show citation
References
- Deacon CF.: Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diab Obes Metab 2011; 13: 7-18.
Go to original source... 
Go to PubMed... - Souhrn údajů o přípravku Januvia (02/2012).
- Souhrn údajů o přípravku Galvus (01/2012).
- Souhrn údajů o přípravku Onglyza (10/2009).
- Souhrn údajů o přípravku Trajenta (08/2011).
- Vella A.: DPP-4 inhibitors - Are They All the Same? Přednáška na sympoziu Incretin Based Therapies, 72. Kongres Americké Diabetologické Asociace, Philadelphia, Pensylvania, USA; dne 9. 6. 2012.
- Pelikánová T, Bouček P.: Léčba pacientů s diabetes mellitus 2. typu a renální insuficiencí. Farmakoterapie 2012; 1: 110-117.